tnfpharma.com (TNFA) - Long-Term Debt to Capital Coefficient

This price chart for TNF Pharmaceuticals (TNFA) illustrates the debt-to-equity ratio, which currently stands at 0.00. The business focuses on developing selective small molecules to combat autoimmune disorders and possesses significant market influence. Despite the risks of logistics disruptions due to conflicts, TNF Pharmaceuticals (TNFA) maintains stability through the neutral status of medicine and its operations in the US.

Developing innovative treatments for inflammatory diseases requires significant capital expenditure in scientific research. The long-term debt-to-equity ratio demonstrates how TNF Pharmaceuticals (TNFA) finances these breakthrough developments. This metric measures the company's reliance on external borrowings with maturities exceeding one year. An increase in this ratio may signal default risks, while a decrease indicates conservative growth. By analyzing the long-term debt-to-equity level, an investor assesses the stability of the business's financial structure.